Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for oral presentation and ten abstracts for poster presentation at the upcoming 7th Bradykinin Symposium, to be held from September 5-6, 2024, in Berlin, Germany. Presentation details are as follows:

• Title: Bradykinin Challenge Model in Humanized Bradykinin B2 receptor Transgenic RatPresenter: Jolanta Skarbaliene, Ph.D.Format: Oral Presentation, Session IIDate, time: Thursday, Sept. 5, 15.05-15.15 CEST (9:05-9:15 a.m. EDT)

• Title: Prophylactic Treatment with Deucrictibant Improves HAE Disease Control and HRQoLPresenter: Markus Magerl, M.D.Format: Oral Presentation, Session VIIDate, time: Friday, Sept. 6, 15.05-15.15 CEST (9:05-9:15 a.m. EDT)

• Title: Long-Term Safety and Efficacy of Oral Deucrictibant for HAE ProphylaxisPresenter: Marc A. Riedl, M.D., M.S.Format: Poster PresentationDate, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)

• Title: Treatment of HAE Attacks with Oral Deucrictibant: RAPIDe-2 Extension ResultsPresenter: Emel Aygören-Pürsün, M.D.Format: Poster PresentationDate, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)

• Title: Prophylaxis of Hereditary Angioedema Attacks with Oral Deucrictibant: CHAPTER-1 ResultsPresenter: Emel Aygören-Pürsün, M.D.Format: Poster PresentationDate, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)

• Title: Deucrictibant vs. Standard of Care in HAE: Propensity Score-Matched AnalysisPresenter: Marc A. Riedl, M.D., M.S.Format: Poster PresentationDate, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)

• Title: Clinical Trials Conformity with AURORA COS: a systematic literature reviewPresenter: Remy Petersen, M.D., Ph.D.Format: Poster PresentationDate, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)

• Title: Cardiovascular safety of repeated oral administration of the B2 receptor antagonist deucrictibantPresenter: Nieves Crespo, Ph.D.Format: Poster PresentationDate, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)

• Title: The bradykinin challenge model translates across rat, monkey and humanPresenter: Juan Bravo, Ph.D.Format: Poster PresentationDate, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)

• Title: Deucrictibant inhibits carrageenan-induced edema in bradykinin B2 receptor transgenic ratPresenter: Anne Lesage, Ph.D.Format: Poster PresentationDate, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)

• Title: A novel kinin biomarker assay for characterization of bradykinin-mediated disordersPresenter: Evangelia Pardali, Ph.D.Format: Poster PresentationDate, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)

• Title: A HMWK capillary immunoblotting assay to characterize bradykinin-mediated disordersPresenter: Evangelia Pardali, Ph.D.Format: Poster PresentationDate, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)

Upon lift of the embargo, the presentation slides and posters will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations.

About PharvarisPharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all types of HAE effective, well-tolerated, and easy-to-administer alternatives to treat attacks, both in the prophylactic and on-demand setting. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is encouraged to further develop deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the on-demand treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks in the coming months. For more information, visit https://pharvaris.com/.

Contact
Maggie Beller
Executive Director, Head of External and Internal Communications
[e-mail]